Skip to main content

Table 1 Demographic and pretreatment clinical characteristics

From: Analysis of long-term oncological results of clinical versus pathological responses after neoadjuvant treatment in locally advanced rectal cancer

  Group 1 Group 2 p value
cCR pCR
n patients (%) 26 (54.2) 22 (45.8)  
Gender (M/F) 13/13 8/14  
Age (years), median (range) 59 (32–82) 55 (26–73) 0.2975
Distance from anal verge (cm), mean (range) 5 (1–12) 7 (2–12) 0.32
T1–2, n (%) 8 (31) 4 (18) 0.5035
T3–4, n (%) 18 (69) 18 (82) 0.5035
cStage III (N+), n (%) 10 (38) 16 (72) 0.04
CRM+, n (%) 7 (27) 13 (59) 0.0515
EMVI+, n (%) 4 (15) 11 (50) 0.0235
LPLN+, n (%) 5 (19) 3 (14) 0.8969
CEA, > 5 ng/dl, n (%) 3 (11) 4 (18) 0.8108
Induction XELOX 3 courses, n (%) 6 (23) 5 (23) 0.7521
Median follow-up—months (range) 47 (6–94) 49.5 (3–112) 0.7848
  1. cCR clinical complete response, pCR pathological complete response, F female, M male, N+ lymph nodes suspected of malignancy, CRM+ circumferential resection margin involved, EMVI + extramural vascular invasion, LPLN lateral pelvic lymph nodes, CEA carcinoembryonic antigen, NS not significant